FULC Fulcrum Therapeutics, Inc. Stock Quote

FULC [NASD]

Index	-	P/E	-	EPS (ttm)	-2.38	Insider Own	1.30%	Shs Outstand	40.64M	Perf Week	-4.28%
Market Cap	199.75M	Forward P/E	-	EPS next Y	-2.84	Insider Trans	-31.07%	Shs Float	37.64M	Perf Month	-28.90%
Income	-89.80M	PEG	-	EPS next Q	-0.66	Inst Own	97.20%	Short Float	9.93%	Perf Quarter	-79.20%
Sales	17.00M	P/S	11.75	EPS this Y	18.10%	Inst Trans	6.78%	Short Ratio	4.10	Perf Half Y	-71.14%
Book/sh	4.65	P/B	1.06	EPS next Y	-6.10%	ROA	-42.30%	Target Price	28.38	Perf Year	-52.14%
Cash/sh	4.81	P/C	1.02	EPS next 5Y	6.40%	ROE	-48.40%	52W Range	3.21 - 33.10	Perf YTD	-72.19%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-38.30%	52W High	-85.13%	Beta	-
Dividend %	-	Quick Ratio	10.90	Sales past 5Y	-	Gross Margin	-	52W Low	53.27%	ATR	0.64
Employees	104	Current Ratio	10.90	Sales Q/Q	-45.80%	Oper. Margin	-	RSI (14)	35.21	Volatility	7.87% 15.16%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-18.20%	Profit Margin	-	Rel Volume	0.43	Prev Close	4.90
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 09 BMO	Payout	-	Avg Volume	912.16K	Price	4.92
Recom	1.70	SMA20	-13.53%	SMA50	-35.24%	SMA200	-68.18%	Volume	392,205	Change	0.41%

Mar-08-22

Initiated

Oppenheimer

Outperform

$33

Mar-03-22

Upgrade

BofA Securities

Underperform → Neutral

Aug-11-21

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$12 → $34

Apr-26-21

Resumed

Credit Suisse

Outperform

$26

Mar-22-21

Initiated

Credit Suisse

Outperform

$26

Mar-02-21

Initiated

Stifel

Buy

$18

Oct-16-20

Initiated

Piper Sandler

Overweight

$22

Aug-12-20

Reiterated

H.C. Wainwright

Buy

$28 → $20

Aug-12-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$11

Aug-12-20

Downgrade

BofA Securities

Neutral → Underperform

$11

Jun-19-20

Downgrade

BofA/Merrill

Buy → Neutral

$19 → $23

Jun-17-20

Initiated

BTIG Research

Buy

$27

Oct-03-19

Initiated

H.C. Wainwright

Buy

$21

Aug-12-19

Initiated

BofA/Merrill

Buy

$19

Jun-10-22 04:02PM	Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -39.18%
08:24AM	Here's Why We're Watching Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation Simply Wall St.
07:02AM	Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial GlobeNewswire
May-12-22 05:08PM	Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria GlobeNewswire +5.14%
May-11-22 12:38PM	Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus Zacks
May-10-22 06:21AM	What Does The Future Hold For Fulcrum Therapeutics, Inc. (NASDAQ:FULC)? These Analysts Have Been Cutting Their Estimates Simply Wall St.
May-09-22 09:55AM	Fulcrum Therapeutics, Inc. (FULC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Zacks -11.24%
08:25AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:00AM	Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results GlobeNewswire
May-06-22 08:00AM	Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-05-22 06:25PM	Alector (ALEC) Reports Q1 Loss, Misses Revenue Estimates Zacks -7.26%
08:00AM	Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference GlobeNewswire
May-04-22 09:15AM	Morphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue Estimates Zacks
May-03-22 09:35AM	After Plunging 59.2% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics, Inc. (FULC) Zacks
May-02-22 08:00AM	Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET GlobeNewswire
Apr-28-22 03:02PM	Earnings Preview: Fulcrum Therapeutics, Inc. (FULC) Q1 Earnings Expected to Decline Zacks
Apr-13-22 07:33AM	Even though Fulcrum Therapeutics (NASDAQ:FULC) has lost US$304m market cap in last 7 days, shareholders are still up 42% over 1 year Simply Wall St. -18.91%
Apr-08-22 08:00AM	Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -6.91%
Apr-04-22 09:35AM	Is the Options Market Predicting a Spike in Fulcrum (FULC) Stock? Zacks
Apr-01-22 08:36AM	Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar? Zacks
08:30AM	Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurologys Annual Meeting GlobeNewswire
Mar-17-22 08:00AM	Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) GlobeNewswire
Mar-14-22 08:00AM	Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference GlobeNewswire
Mar-11-22 08:00AM	Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-07-22 10:00AM	Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 179% as Wall Street Analysts Expect? Zacks +14.35%
Mar-03-22 11:24AM	Fulcrum Therapeutics To Start Late-Stage Losmapimod Trial In Rare Muscle Wasting Disorder Benzinga +5.41%
08:35AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:01AM	Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
07:00AM	Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) GlobeNewswire
Feb-24-22 09:15AM	Vericel Corporation (VCEL) Q4 Earnings Miss Estimates Zacks +5.82%
08:00AM	Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET GlobeNewswire
Feb-15-22 06:53PM	2 Strong Buy Stocks That Could Be Bought Out, According to Credit Suisse TipRanks +7.32%
Feb-12-22 07:33AM	Multiple insiders bought Fulcrum Therapeutics, Inc. (NASDAQ:FULC) stock earlier this year, a positive sign for shareholders Simply Wall St.
Feb-11-22 08:00AM	Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Feb-10-22 08:00AM	Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-07-22 05:38PM	Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ... GuruFocus.com
Jan-19-22 09:38PM	Mass General Brigham, Inc Buys DocuSign Inc, Oyster Point Pharma Inc, Dada Nexus, Sells iShares ... GuruFocus.com
Jan-12-22 02:58PM	Hedge Funds Are Crazy About Fulcrum Therapeutics, Inc. (FULC) Insider Monkey
Jan-10-22 07:00AM	Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases GlobeNewswire
Jan-07-22 08:00AM	Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-06-22 08:00AM	Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire -7.34%
Jan-04-22 08:00AM	Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer GlobeNewswire
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... GuruFocus.com
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... GuruFocus.com
Dec-14-21 05:59AM	We're Hopeful That Fulcrum Therapeutics (NASDAQ:FULC) Will Use Its Cash Wisely Simply Wall St.
Dec-06-21 07:00AM	Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data GlobeNewswire
Nov-17-21 08:00AM	Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors GlobeNewswire
Nov-04-21 08:35AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results GlobeNewswire
Nov-03-21 07:00AM	Fulcrum Therapeutics to Participate in Upcoming November Investor Conferences GlobeNewswire
Oct-28-21 07:00AM	Fulcrum Therapeutics to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET GlobeNewswire
Oct-14-21 10:05AM	Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect? Zacks
Oct-01-21 07:00AM	Fulcrum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-21-21 01:59PM	Shares Of Fulcrum Therapeutics Inc. Rise Above Previous 52-Week High Benzinga
Sep-20-21 07:00AM	Fulcrum Therapeutics Announces Multiple Presentations During the Virtual Congress of the World Muscle Society GlobeNewswire
Sep-10-21 07:00AM	Fulcrum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-08-21 07:00AM	Fulcrum Therapeutics Appoints Mel Hayes as Chief Commercial Officer GlobeNewswire -5.34%
Sep-02-21 07:00AM	Fulcrum Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-23-21 06:47AM	2 Soaring Biotech Stocks With More Fuel in the Tank Motley Fool
Aug-16-21 04:01PM	Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares GlobeNewswire -5.19%
11:51AM	Is Fulcrum Stock a Buy Right Now? This Is What You Need to Know TipRanks
06:16AM	News Flash: Analysts Just Made An Incredible Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts Simply Wall St.
Aug-12-21 01:33AM	Earnings Beat: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St. +11.14%
Aug-11-21 10:09PM	Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock GlobeNewswire +7.62%
04:06PM	Why Fulcrum Therapeutics Popped Again on Tuesday Motley Fool
Aug-10-21 04:24PM	Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +125.33%
04:04PM	Fulcrum Stock Nearly Triples Why Shares Went Gangbusters On Sickle Cell Drug Investor's Business Daily
10:56AM	Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today Motley Fool
09:05AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:01AM	Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results GlobeNewswire
07:00AM	Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease GlobeNewswire
Aug-04-21 07:00AM	Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET GlobeNewswire
Aug-03-21 03:00PM	Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-30-21 11:14AM	Were Hedge Funds Right About Fulcrum Therapeutics, Inc. (FULC)? Insider Monkey
Jul-01-21 01:25AM	Independent Director James Geraghty Just Bought 12% More Shares In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Simply Wall St.
Jun-24-21 07:00AM	Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function GlobeNewswire
Jun-21-21 07:00AM	Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC) GlobeNewswire
May-12-21 04:19PM	Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation Benzinga
07:00AM	Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) GlobeNewswire
02:08AM	News Flash: Analysts Just Made A Huge Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts Simply Wall St.
May-07-21 07:00AM	Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference GlobeNewswire
05:09AM	A Look At Fulcrum Therapeutics' (NASDAQ:FULC) Share Price Returns Simply Wall St.
May-06-21 08:55AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates Zacks +5.06%
07:01AM	Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results GlobeNewswire
07:00AM	Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer GlobeNewswire
06:15AM	Fulcrum Therapeutics Inc to Host Earnings Call ACCESSWIRE
Apr-29-21 07:00AM	Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET GlobeNewswire
Apr-09-21 01:15PM	Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference GlobeNewswire
Mar-24-21 09:29AM	Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development GlobeNewswire
Mar-18-21 11:30AM	Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference GlobeNewswire -7.66%
Mar-04-21 08:25AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates Zacks -14.32%
07:01AM	Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
07:00AM	Fulcrum Therapeutics Announces CEO Transition GlobeNewswire
06:15AM	Fulcrum Therapeutics Inc to Host Earnings Call ACCESSWIRE
Feb-26-21 07:00AM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET GlobeNewswire
07:00AM	Fulcrum Therapeutics Recognizes Rare Disease Day 2021 GlobeNewswire
Feb-19-21 07:00AM	Fulcrum Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +8.27%
Feb-17-21 02:47AM	What Type Of Shareholders Own The Most Number of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares? Simply Wall St.
Jan-22-21 04:00PM	Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares GlobeNewswire
Jan-19-21 10:34PM	Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +6.64%

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gould Robert J	Director	Jun 07	Option Exercise	7.84	71,435	560,050	578,065	Jun 08 07:33 PM
Gould Robert J	Director	Jun 07	Sale	8.09	71,435	577,895	506,630	Jun 08 07:33 PM
Gould Robert J	Director	Jun 06	Option Exercise	7.84	24,382	191,155	531,012	Jun 06 07:00 PM
Gould Robert J	Director	Jun 06	Sale	8.10	24,382	197,592	506,630	Jun 06 07:00 PM
Gould Robert J	Director	Jun 03	Option Exercise	7.84	25,551	200,320	532,181	Jun 06 07:00 PM
Gould Robert J	Director	Jun 03	Sale	7.95	25,551	203,056	506,630	Jun 06 07:00 PM
Gould Robert J	Director	Jun 02	Option Exercise	7.84	16,689	130,842	523,319	Jun 06 07:00 PM
Gould Robert J	Director	Jun 02	Sale	7.92	16,689	132,162	506,630	Jun 06 07:00 PM
Gould Robert J	Director	Apr 07	Option Exercise	7.84	5,631	44,147	512,261	Apr 11 05:00 PM
Gould Robert J	Director	Apr 07	Sale	24.02	5,631	135,228	506,630	Apr 11 05:00 PM
Gould Robert J	Director	Apr 05	Option Exercise	7.84	52,552	412,008	559,182	Apr 05 07:00 PM
Gould Robert J	Director	Apr 05	Sale	24.26	52,552	1,274,775	506,630	Apr 05 07:00 PM
Gould Robert J	Director	Apr 04	Option Exercise	7.84	7,235	56,722	513,865	Apr 05 07:00 PM
Gould Robert J	Director	Apr 04	Sale	24.02	7,235	173,749	506,630	Apr 05 07:00 PM
Gould Robert J	Director	Apr 01	Option Exercise	7.84	34,464	270,198	541,094	Apr 05 07:00 PM
Gould Robert J	Director	Apr 01	Sale	24.03	34,464	828,160	506,630	Apr 05 07:00 PM
Stuart Bryan	See Remarks	Aug 11	Option Exercise	7.84	28,000	219,520	28,000	Aug 12 04:20 PM
Stuart Bryan	See Remarks	Aug 11	Sale	23.75	28,000	665,000	0	Aug 12 04:20 PM
Stuart Bryan	See Remarks	Aug 10	Option Exercise	7.84	32,000	250,880	32,000	Aug 12 04:20 PM
Moxham Christopher	Chief Scientific Officer	Aug 10	Option Exercise	7.84	51,785	405,994	31,071	Aug 12 04:20 PM
Stuart Bryan	See Remarks	Aug 10	Sale	17.50	32,000	560,000	0	Aug 12 04:20 PM
Moxham Christopher	Chief Scientific Officer	Aug 10	Sale	17.60	51,785	911,416	0	Aug 12 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience